SCHEMBL6783151

SCHEMBL6783151

COc1cc(OC)cc(N2CCN(C(=O)Nc3cc4ccccc4cc3OC)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 3/20 0.60
KMT2A Q03164 3/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 3/20 0.57
ALDH1A1 P00352 3/20 0.57
LMNA P02545 2/20 0.57
TP53 P04637 2/20 0.57
MAPK1 P28482 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HSD17B10 Q99714 4/20 0.53
POLB P06746 3/20 0.53
USP2 O75604 2/20 0.53
TSHR P16473 2/20 0.53
ALOX15 P16050 1/20 0.53
KDM4E B2RXH2 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
PKM P14618 1/20 0.51
HCAR2 Q8TDS4 1/20 0.51
NAMPT P43490 1/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782052 0.91 RBP4 (0.58) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6776851 0.91 RBP4 (0.67) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6781384 0.90 RBP4 (0.57) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6966493 0.87 RBP4 (0.56) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6960617 0.83 KMT2A (0.53) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6956583 0.83 KMT2A (0.53) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6967271 0.82 RBP4 (0.51) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6956065 0.80 RBP4 (0.49) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6965253 0.80 RBP4 (0.49) RBP4KMT2AGAAMAPTALDH1A1
SCHEMBL6960722 0.80 RBP4 (0.71) RBP4KMT2AGAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS RBP4 4204/4885KMT2A 2664/4885GAA 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.